Quantcast

Latest biopharmaceutical Stories

2014-04-30 08:32:32

ATLANTA, April 30, 2014 /PRNewswire/ -- Today, the U.S. Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB, and health data sharing network PatientsLikeMe(®) presented the results of the Policy for Optimal Epilepsy Management (POEM) study at the 66(th) Annual Meeting of the American Academy of Neurology in Philadelphia, Pa. This first-time, real-world study of an online health management platform demonstrated statistically significant...

2014-04-29 23:22:06

Gallus BioPharmaceuticals, a premier pure-play biologics contract development and manufacturing organization and Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT), jointly announced finalization of a multi-stage manufacturing services agreement. St. Louis, Missouri (PRWEB) April 29, 2014 Gallus BioPharmaceuticals, LLC(Gallus), a premier pure-play biologics contract development and manufacturing...

2014-04-29 08:35:33

MONROVIA, Calif., April 29, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 4:50 p.m. EDT in Boston, MA. A live audio webcast of the...

2014-04-28 08:30:56

ATLANTA and MELBOURNE, Australia, April 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive five-year agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN®, Alimera's sustained release intravitreal injection for...

2014-04-15 16:27:51

AUSTIN, Texas, April 15, 2014 /PRNewswire/ -- XBiotech announced today that Robert Lindsey has joined the Company as Senior Vice President Corporate Development & General Counsel. Mr. Lindsey joins XBiotech from Dell where he served as Legal Director. In that capacity, Mr. Lindsey acted as the sole securities counsel for Dell and was the primary attorney responsible for the treasury, accounting, investor relations, corporate communications and internal audit groups. Most recently,...

2014-04-11 23:01:51

Transparency Market Research Report Added "Biosimilar And Follow-On Biologics Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018" to its database. Browse Full Report - http://www.transparencymarketresearch.com/biosimilar-and-follow-on-biologics-market.html. Albany, New York, USA (PRWEB) April 11, 2014 There is a rising demand for low cost biological drugs. Commercial and regulatory developments are taking the follow-on biologics market to new...

2014-04-10 08:29:30

MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a milestone payment from Merck, through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb® antibody...

2014-04-10 08:28:53

NEW YORK, April 10, 2014 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic...

2014-04-02 16:30:36

SEATTLE, and COPHENHAGEN, Denmark, April 2, 2014 /PRNewswire/ -- CMC Biologics, a leading global contract manufacturing organization known for technical excellence and customer satisfaction in biopharmaceutical development and commercial manufacture of protein based therapeutics, was recognized again in 2014 for innovation, quality and reliability by Life Science Leader at an awards ceremony at DCAT Week14 in New York last month....

2014-04-01 08:29:19

Expanding Product Offerings; Building IP Portfolio; Seeking Global Marketing Partners NEW YORK, April 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.